公开(公告)号：US20230119665A1

公开(公告)日：2023-04-20

申请号：US17823910

申请日：2022-08-31

申请人： Cytokinetics, Inc.

发明人： Chihyuan CHUANG ,  Bradley P. MORGAN ,  Mark VANDERWAL ,  Wenyue WANG ,  Luke W. ASHCRAFT

IPC分类号： C07D413/12 ,  C07D413/10 ,  C07D271/06 ,  C07D413/14 ,  A61P9/04 ,  A61P9/00 ,  C07D403/12 ,  C07D401/12 ,  C07D231/14 ,  C07D413/04 ,  C07D417/12 ,  C07F5/02

摘要： Provided are compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein A, Z, B, R1, R2, R3, G1, G2, and G3 are as defined herein.
Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
Also provided are methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20230090256A1

公开(公告)日：2023-03-23

申请号：US17736895

申请日：2022-05-04

申请人： Cytokinetics, Inc.

发明人： Chihyuan CHUANG ,  Bradley P. MORGAN ,  Mark VANDERWAL ,  Luke W. ASHCRAFT ,  Kevin LAU

IPC分类号： C07D487/10 ,  C07D491/107 ,  C07D241/08 ,  C07D241/38 ,  C07D401/04 ,  C07D401/06 ,  C07D401/08 ,  C07D403/08 ,  C07D405/04 ,  C07D405/12 ,  C07D405/14 ,  C07D409/14 ,  C07D413/08 ,  C07D413/14 ,  C07D417/08 ,  A61P9/04

摘要： Provided are compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R2A, R2B, R3, R4, and R5 are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20190256504A1

公开(公告)日：2019-08-22

申请号：US16252483

申请日：2019-01-18

申请人： Cytokinetics, Inc.

发明人： Chihyuan CHUANG ,  Bradley P. MORGAN ,  Mark VANDERWAL ,  Wenyue WANG ,  Luke W. ASHCRAFT

IPC分类号： C07D413/12 ,  A61P9/00 ,  C07D413/10 ,  C07D271/06 ,  C07F5/02 ,  C07D413/14

摘要： Provided are compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein A, Z, B, R1, R2, R3, G1, G2, and G3 are as defined herein.Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof.Also provided are methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20210276991A1

公开(公告)日：2021-09-09

申请号：US17255379

申请日：2019-06-25

申请人： Cytokinetics, Inc.

发明人： Bradley P. MORGAN ,  Mark VANDERWAL ,  Chihyuan CHUANG

IPC分类号： C07D413/14 ,  C07D413/12 ,  C07D271/06

摘要： Provided are compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R2, Y1, Y2, L1, and G1 are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20210147399A1

公开(公告)日：2021-05-20

申请号：US17013472

申请日：2020-09-04

申请人： Cytokinetics, Inc.

发明人： Chihyuan CHUANG ,  Bradley P. MORGAN ,  Mark VANDERWAL ,  Wenyue WANG ,  Luke W. ASHCRAFT

IPC分类号： C07D413/12 ,  A61P9/00 ,  C07D271/06 ,  C07D413/10 ,  C07D413/14 ,  C07F5/02 ,  C07D413/04 ,  C07D403/12 ,  C07D417/12 ,  C07D401/12 ,  A61P9/04 ,  C07D231/14

摘要： Provided are compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein A, Z, B, R1, R2, R3, G1, G2, and G3 are as defined herein.
Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
Also provided are methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof.